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Abstract
Background: Aberrant DNA methylation of CpG islands of cancer-related genes is among the earliest and most
frequent alterations in cancerogenesis and might be of value for either diagnosing cancer or evaluating recurrent
disease. This mechanism usually leads to inactivation of tumour-suppressor genes. We have designed the current
study to validate our previous microarray data and to identify novel hypermethylated gene promoters.
Methods: The validation assay was performed in a different set of 8 patients with colorectal cancer (CRC) by
means quantitative reverse-transcriptase polymerase chain reaction analysis. The differential RNA expression
profiles of three CRC cell lines before and after 5-aza-2'-deoxycytidine treatment were compared to identify the
hypermethylated genes. The DNA methylation status of these genes was evaluated by means of bisulphite
genomic sequencing and methylation-specific polymerase chain reaction (MSP) in the 3 cell lines and in tumour
tissues from 30 patients with CRC.
Results: Data from our previous genome search have received confirmation in the new set of 8 patients with
CRC. In this validation set six genes showed a high induction after drug treatment in at least two of three CRC
cell lines. Among them, the N-myc downstream-regulated gene 2 (NDRG2) promoter was found methylated in all
CRC cell lines. NDRG2 hypermethylation was also detected in 8 out of 30 (27%) primary CRC tissues and was
significantly associated with advanced AJCC stage IV. Normal colon tissues were not methylated.
Conclusion: The findings highlight the usefulness of combining gene expression patterns and epigenetic data to
identify tumour biomarkers, and suggest that NDRG2 silencing might bear influence on tumour invasiveness, being
associated with a more advanced stage.
Published: 3 March 2009
BMC Medical Genomics 2009, 2:11 doi:10.1186/1755-8794-2-11
Received: 20 June 2008
Accepted: 3 March 2009
This article is available from: http://www.biomedcentral.com/1755-8794/2/11
© 2009 Piepoli et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical Genomics 2009, 2:11 http://www.biomedcentral.com/1755-8794/2/11
Page 2 of 12
(page number not for citation purposes)
Background
Colorectal cancer (CRC) is the third most common cancer
in men and women, accounting for 11% of all cancer-
related deaths. The majority of cases are diagnosed in
advanced stages when a curative treatment is less likely to
occur and chemotherapy is the only option [1]. The iden-
tification of the molecular, genetic, and epigenetic
changes underlying the adenoma-carcinoma sequence [2]
leading to CRC has been the focus of many researches [3].
It is now widely accepted that sporadic CRC frequently
arises from preneoplastic lesions through the activation of
proto-oncogenes, such as K-ras, and the inactivation of
tumor suppressor genes (TSG), such as APC, p53, DCC,
and the mismatch repair genes [4,5]. Apart from muta-
tions, gene expression may also be modified by altering of
DNA methylation [6]. Two general phenomena have until
now been observed. The first one is global DNA
hypomethylation with decreased 5-methylcytosine con-
tent which results in both enhanced expression of proto-
oncogenes [7] and genomic instability [8]. The second
event is represented by local DNA hypermethylation of
CpG islands, short sequences rich in CpG dinucleotides in
the 5'untranscribed region (5'-UTR). This event occurs in
approximately half of all human genes [9,10] silences spe-
cific TSG, and accelerates cancer formation [11,12]. Treat-
ment with DNA demethylating drugs, such as 5-aza-2'-
deoxycytidine (5-Aza-CdR or Decitabine), was shown to
reverse the hypermethylation and restore expression of
TSG [13]. Therefore, cancer-specific promoter methyla-
tion may by itself serve as a valuable clue to uncover novel
TSG.
In the present study, we aimed to uncover novel targets of
promoter methylation in CRC, by combining gene expres-
sion profile data, already highlighted by our group [14],
with results of demethylating assay and in silico screening
for CpG islands.
Methods
Patients
Peripheral blood, primary tumour and matching normal
tissue samples from a cohort of 30 consecutive CRC
patients undergoing curative surgery at our Institution
were collected. Clinical data, tumour location, and AJCC
staging of these patients are shown in Table 1. Primary
tumour and matching normal tissue samples were
obtained from a second cohort of 8 CRC patients, and
used in a validation assay. Genomic DNA was isolated
from peripheral blood samples using standard tech-
niques. Tissue samples were immediately frozen in liquid
nitrogen and stored at -80°C until nucleic acids extrac-
tion. The study was approved by the Ethics Committee at
our Institution, and all patients gave their informed writ-
ten consent.
RNA extraction from fresh frozen tissue
About 150–200 mg fresh frozen tissues were used to iso-
late total RNA by phenol extraction (TRIzol Reagent, Inv-
Table 1: Clinical data of colorectal cancer (CRC) patients
CRC
n = 30 (%)
Age (yrs):
Mean (± SD) 59 ± 14
Sex:
Male/Female 15/15
Tumour location:
Ascending colon 7 (23%)
Transverse colon 2 (7%)
Descending colon 4 (13%)
Sigmoid colon 8 (27%)
Rectum 4 (13%)
Rectum-Sigmoid colon 5 (17%)
AJCC stage:
01  ( 3 % )
I3  ( 1 0 % )
IIa 8 (27%)
IIIb 3 (10%)
IIIc 1 (3%)
IV 14 (47%)
Age (yrs):
Mean age <50 41 ± 7
CRC:
Familiar/Sporadic 1/8
Tumour location:
Ascending colon 1 (11%)
Descending colon 2 (22%)
Sigmoid colon 4 (45%)
Rectum 1 (11%)
Rectum-Sigmoid colon 1 (11%)
AJCC stage:
I1  ( 1 1 % )
IIIb 2 (22%)
IIIc 1 (11%)
IV 5 (55%)
Age (yrs):
Mean age >50 66 ± 9
CRC:
Familiar/Sporadic 8/13
Tumour location:
Ascending colon 6 (29%)
Transverse colon 2 (9%)
Descending colon 2 (9%)
Sigmoid colon 4 (19%)
Rectum 3 (15%)
Rectum-Sigmoid colon 4 (19%)
AJCC stage:
01  ( 5 % )
I2  ( 9 % )
IIa 8 (38%)
IIIb 1 (5%)
IV 9 (43%)BMC Medical Genomics 2009, 2:11 http://www.biomedcentral.com/1755-8794/2/11
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itrogen Corporation, Carlsbad, CA, USA) which was
subsequently purified by column chromatography (RNe-
asy Mini Kit, Qiagen, Valencia, CA, USA). RNA integrity
was monitored using MOPS gel electrophoresis.
Cell culture, 5-Aza-CdR Treatments
The HCT116, CaCo2 and SW480 cell lines were pur-
chased from the American Type Culture Collection
(ATCC, Rockville, MD, USA), and maintained in DMEM
medium (Invitrogen Corporation, Carlsbad, CA) supple-
mented with 10% FBS, 100 U/ml penicillin, and 100 μg/
ml streptomycin in a humidified 5% CO2 atmosphere at
37°C. For demethylation studies, cells were seeded at a
density of 1 × 106 cells per 100-mm dish, and incubated
for 24 hrs in a growth media. Subsequently, 5-Aza-CdR
(Merck Chemicals Ltd., Nottingham, UK) was added to
the incubation mixture following two different protocols.
In the acute treatment 1 μM 5-Aza-CdR was added to incu-
bation mixture for 24 hrs; afterwards, the medium was
changed once daily for 3 consecutive days; DNA and RNA
content were checked at 2nd, 4th and 6th days [15,16]. In
the chronic treatment, 2 μM 5-Aza-CdR was added for 24
hrs at day 1st, 3rd and 5th [17]; at each experimental day,
the cells were placed in fresh medium and harvested at
day 6th to isolate DNA and RNA.
qPCR Assay
For qPCR, 1.0 μg of total RNA from CRC cell lines and
normal and tumour tissues of the second cohort of CRC
samples was used with hexamer random primers to run
the first strand cDNA synthesis by the RT-System kit
(Promega Corporation, Madison, WI). Oligonucleotide
sequences were designed by means of the PrimerExpress
program (Applied Biosystems, Applera, Foster City, CA)
with default parameters in every case; whenever possible,
the oligos were designed to span an intron region (Table
2). To ensure specificity, amplicon sequences were
checked by both BLAST and BLAT programs against the
human genome. The efficiency of each oligo pairs was
checked by diluting a series of control cDNAs. All qPCRs
were performed in a 10-μl final volume, in three replicates
per sample, set up in a 384-well plate format with the
Biomek 2000 robot (Beckman Coulter, Inc., Miami, FL).
The assays were run in an ABI 7900 Sequence Detection
System (Applied Biosystems, Applera, Foster City, CA,
USA) with the following amplification conditions: 50°C
for 2 min, 95°C for 10 min, and 50 cycles at 95°C for 15
s and at 60°C for 1 min. Expression of mRNA from candi-
date genes was analysed quantitatively by means of SYBR
Green Real Time PCR (Invitrogen Corporation, Carlsbad,
CA) and raw Ct values calculated with SDS2.0.
In Silico Search and Bisulfite Sequencing Analysis (BSA)
The presence of CpG islands, overlapping the 5'-UTR, was
examined by means of the MethPrimer http://www.uro
gene.org/methprimer/, according to CpG islands defini-
tion.
Bisulfite modification of DNA from colon cancer cell
lines, peripheral blood and frozen tissues of patients was
assayed, as reported by Herman et al. [18]; normal lym-
phocytes (NL) and in vitro methylated DNA (IVD) were
used as negative and positive controls, respectively. In the
assay, 1 μg of DNA was denaturated by treatment with
NaOH at 37°C for 10 min, followed by incubation with
hydroquinone and sodium bisulfite at 50°C for 16–17 h
in the dark. After treatment, DNA was purified using DNA
cleanup kit (Promega Corporation, Madison, WI), incu-
bated with NaOH at 37°C for 15 min, precipitated with
ammonium acetate and 100% ethanol, washed with 70%
ethanol and, finally, re-suspended in 25 μl of distilled
water. DNA methylation patterns in the CpG islands were
determined by BSA using the primers listed in Table 2. The
PCR conditions were 3 min at 94°C, 30 cycles of 94°C for
30 sec, specific annealing temperature for 30 sec, and
72°C for 60 sec. The sequence of the PCR products was
analysed by using Sequencing Analysis 3.4.1 (Applied
Biosystems, Applera, Foster City, CA, USA).
MSP Assay
Qualitative analysis of CpG islands in the promoter
region of the NDRG2, p16, APC, and MLH1 genes in 30
patients of CRC, in cell lines, in NL and IVD was carried
out by MSP assay [18]. The primers for unmethylated and
methylated DNA are listed in Table 2. For the NDRG2 pro-
moter region we used two different primers
(NDRG2_UnM/NDRG2_M and NDRG2_UnM2/
NDRG2_M2) to cover the same region sequenced by the
bisulfite assays. PCR reaction was carried out in a 25 μl
mixture containing 0,2 mM each dNTP, 1.5 mM MgCl2,
primers (10 μM each), bisulfite-modified DNA (50 ng),
and 0.75 U of Amplitaq Taq Gold polymerase (Applied
Biosystems, Applera, Foster City, CA) for 35 cycles (95°C
for 12 min, 94°C for 1 min, TA for 1 min, then 72°C for
1 min, followed by a final extension at 72° for 5 min) and
analysed on a 3% agarose gel stained with ethidium bro-
mide. All reactions were run in duplicate to ensure con-
sistent and reproducible results.
Statistical Analysis
We carried out three separate statistical analyses. In the
initial analysis, qPCR data were used to validate our pre-
vious array results [14]. Calculations were made using the
Comparative CT method [19,20]. We used three genes,
that is hEEF1A1, hGAPDH and hHRPT1, to normalize
input cDNA for each sample, with cDNA of normal tissue
used as calibrator. The chi-square method with one degree
of freedom (χ2
1), calculated by BMDP Statistical Software
(BMDP Statistical Software, Cork Technology Park, Model
Farm Road, Cork, Ireland) [21], was used to asses statisti-BMC Medical Genomics 2009, 2:11 http://www.biomedcentral.com/1755-8794/2/11
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cal significance of expression difference for each gene of
the 8 paired samples. The second analysis concerned the
variation of gene expression before and after 5'-Aza-CdR
treatment by means of the T test, calculated by BMDP Sta-
tistical Software. Expression level of the post-treatment
specimen compared to the pre-treatment specimen was
calculated as a log-transformed ratio. A gene was classified
as up-regulated following the 5-Aza-CdR treatment when
relative mRNA expression was greater or equivalent to
1.65-fold in at least one treatment condition in one cell
line. Genes with no change or very low expression levels
in post treatment specimens were no further considered in
the analysis.
The final part of our analysis evaluated the BSA data. The
median number of full CpG islands, present in normal
and tumour tissues, was calculated and compared in
tumour (T) matched normal (N) tissue of the same
patients. The χ2
1 method was used to asses significant dif-
ference; a number of CpG islands higher than 5 was taken
as statistically significant.
Table 2: Primer Sequences and Conditions for qRT-PCR, Bisulfite sequencing and MSP Analysis
Gene symbol RefSeq mRNA Primer Forward (5'-->3') Primer Reverse (5'-->3') Size 
(bp)
AT† 
(°C)
Quantitative Real Time PCR (qPCR) assay
ABCA8 NM_007168 CCATCATGGTATCTGGGAGGTT GCAGGTAATCTTTGCCAAATTTG 77 60
AQP8 AB013456 CACGGGCTGGCTTTGG CCAGTACGGGAGGAGCATCA 128 60
CLCA4 NM_012128 CAAAATGGCCTATCTCAGTATTCCA TCGCTTTGGCTTGAAGATTGT 68 60
HPGD1 NM_000860 GCATGGCATAGTTGGATTCACA AAGCCTGGACAAATGGCATT 83 60
PRDX6 NM_004905 GCCCTTTCAATAGACAGTGTTGAG ATCGATGATGGGAAAAGGTAACTT 104 60
SLC26A3 NM_000111 ATCGTTGGAACTGATGATGACTTC CAGCATCATGGATTGTTAAGAAAAA 90 60
STX12 NM_177424 AAGAAAGAGAAACGGCAATTCG TCATGGCCAAATCTTTAAATATCTGA 75 60
CSE1L NM_001316 CGGTTCAAACACAATAGCAAGTG GGATGCAATCAGCTTCTGAAAGA 78 60
HSPH1 NM_00664 AACAAAATCCCAGATGCTGACA ACCTTTATTTTGGGCTTTTTAGCTT 79 60
NEBL1 HSY1624 ATCCATGAGATCAATGCAGCAT CATCCTGGGCACTGTAATCGT 73 60
RFC3 NM_002915 CTGAGGGAGACTGCAAATGCT ACAGCCTTCCACGAACTTCAA 72 60
SLC12A2 NM_001046 AAGGAACATTCAAGCACAGCTAATATT TGCCATGTAGAGAGCACTAGACACA 86 60
SOX9 NM_000346 ACGCCGAGCTCAGCAAGA CACGAAGGGCCGCTTCT 70 60
GTF2IRD1 ENST00000265755 AATCTGCAATGATGCCAAGGT CCGAGACCCGCTTTCTCTT 70 60
MXI1 NM_005962 CGGCACACAACACTTGGTTT GGCTTTTTCTTTCAGCTTCTTCA 75 60
NR3C2 NM_000901 TTCATTCTCAGTACCAATAAAGCAAGA GGTTTACTGTTGGATTCCCTTTAAAA 82 60
SGK1 NM_005627 AGGAGCCTGAGCTTATGAATGC GACGACGGGCCAAGGTT 75 60
NDRG2 NM_201535 CTGACCGAGGCCTTCAAGTACT GGCGAGTCATGCAGGATGA 66 60
TPX2 NM_012112 AGCCCTTTGTTCCCAAGAAAG CCAGCTGAAAAGGTTCCTGAA 80 60
UBE2C NM_181799 TGGAGCTTACTCTGCAACTGTTTC CCAAATGCCAGAACCCAACATTGATAGTCC 74 60
CCNB1 NM_031966 CCTGGCTAAGAATGTAGTCATGGTAA GCATGCTTCGATGTGGCATA 83 60
SCNN1B ENST00000343070 CATTGAAGAATCAGCAGCCAATA CCCATCCAGAAGCCAAACTG 74 60
FOXM1 U74613 AGCAAGCGAGTCCGCATT CTGCAGAAGAAAGAGGAGCTATCC 68 60
SGK2 NM_016276 ACATCATTTACAGGGATCTGAAACC TCCTTGCAGAGGCCAAAATC 87 60
Bisulfite Sequencing Analysis (BSA)
NDRG2 TTTTCGAGGGGTATAAGGAGAGTTTATTTT CCAAAAACTCTAACTCCTAAATAAACA 320 53
CSE1L GTTTGGAATTTTAGTATTTTGGGAG CTCTAACCATACCAACAAACTTCAC 285 60
HSP1 GGAGAGGGTTTGGGTATGTAA CAAAAAAATAAAATAAACCTAAAAAAC 194 56
PRDX6 TATTTTTTTGTAGGGAGTTGGT TAACATCCTTCAAACACTATAAACC 279 56
SOX9 TTTTTATTGATTTTTTTTGTAAAAG ATACCAAAATTTTAATACCTTCTCC 388 53
Methylation-Specific PCR (MSP) assay?
NDRG2_UnM AGAGGTATTAGGATTTTGGGTATGA CCACTAAAAAAACAAAAATCTCACC 125 55
NDRG2_M AGAGGTATTAGGATTTTGGGTACG GCTAAAAAAACGAAAATCTCGC 123 55
NDRG2_UnM_2 GGTAAATTTATTTGGGTATTGA CAAAAACAAAATTAACCCTACAAA 210 54
NDRG2_M_2 TAGTGGTAAATTTATTCGGGTATCG CAAAAACGAAATTAACCCTACGA 214 62
p16-UnM TTATTAGAGGGTGGGGTGGATTGT CAACCCCAAACCCACAACCATAA 151 65
p16-M TTATTAGAGGGTGGGGCGGATCGC GACCCCCGAACCGCGAACCGTAA 150 68
APC-UnM GTGTTTTATTGTGGAGTGTGGGTT CCAATCAACAAACTCCCAACAA 108 63
APC-M TATTGCGGAGTGCGGGTC ACCACCTCATCATAACTACCCACA 98 63
MLH1-UnM TTTTGATGTAGATGTTTTATTAGGTTGT ACCACCTCATCATAACTACCCACA 124 60
MLH1-M ACGTAGACGTTTTATTAGGGTCGC CCTCATCGTAACTACCCGCG 115 60
?UnM = unmethylated sequence; M = methylated sequence.
† AT = annealing temperature.BMC Medical Genomics 2009, 2:11 http://www.biomedcentral.com/1755-8794/2/11
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Results
qPCR validation of deregulated genes
Among the genes higlighted as significantly deregulated in
our previous microarray study [14], 24 genes were
selected for further validation by using the quantitative
Real-Time PCR (qPCR), based on their cellular function,
such as transport, signal transduction, intracellular and
cell surface signalling, cell cycle, replication-repair of
DNA, and protein folding. (Table 3).
qPCR assay was applied to analyse mRNA expression of
the 24 selected genes, as well as of three control house-
keeping genes (GAPDH, EEF1A1 and  HRPT1) in the
tumour and normal tissues taken from new cohort of 8
patients with CRC.
Compared to normal tissue with an expression profile
normalized to 1, in tumour samples 7 genes (ABCA8,
AQP8, CLCA4, HPGD1, PRDX6, SLC26A3, and STX12)
were uniformly under expressed in all 8 CRC patients, 3
genes (MXI1, NDRG2 and SCNN1B) in 7 patients, and 3
other genes (SGK2, NR3C2, and SGK1) in 6 patients. Eight
genes, that is CSE1L, GTF2IRD1, HSPH1, NEBL1, RFC3,
SLC12A2, FOXM1 and  SOX9, were specifically over-
expressed in tumour tissues from 7 patients (Fig. 1). The
remaining 3 genes (TPX2, UBE2C, CCNB1) were excluded
from the analysis because of indeterminate qPCR values.
In general, qPCR results were in agreement with the
microarray data.
Gene expression before and after 5-Aza-CdR in colon cell 
lines
To investigate the role of methylated CpG islands in the
modulation of gene expression, HCT-116, CaCo2 and
SW480 human colon cancer cell lines were cultured with
different doses of 5-Aza-CdR to induce a demethylation
event, and gene expression levels were measured by
means of qPCR. Two 5-Aza-CdR challenge regimens were
Table 3: List of genes selected from microarrays analysis comparing normal mucosa matched tumour colon tissue. The different 
expression in tumoural tissue was showed.
Function/category Gene Accession no. Microarray Data Gene description
P value Expression
Insulin Receptor Signaling SGK1 NM_005627.1 0.059 down Serum glucocorticoid regulated kinase (SGK)
Transport CLCA4 NM_012128.2 0.052 down chloride channel, calcium activated, family 
member 4
Transport SLC26A3/DRA NM_000111.1 0.044 down solute carrier family 26, member 3 
(SLC26A3)
Transport AQP8 NM_001169.1 0.052 down aquaporin 8
Transport SCNN1B NM_000336.1 0.046 down sodium channel, nonvoltage-gated 1, beta 
(S. Liddle)
Transport (ATP binding) ABCA8 NM_007168.1 0.040 down ATP-binding cassette, sub-family A (ABC1), 
member 8
Protein transport STX12 AI816243 0.051 down syntaxin 12
Receptor activity (mineralcorticoid) NR3C2 NM_000901.1 0.049 down nuclear receptor subfamily 3, group C, 
member 2
Cell cycle (proliferation) MXI1 NM_005962.1 0.053 down MAX-interacting protein 1 (MXI1)
Cell cycle (differentiation) NDRG2 NM_016250.1 0.039 down N-myc downstream-regulated gene 2
Prostaglandin metabolism HPGD J05594.1 0.050 down hydroxyprostaglandin dehydrogenase 15-
(NAD)
Prostaglandin and leukotriene 
Metabolism
PRDX6 NM_004905.1 0.050 down peroxidase, acidic calcium-independent 
phospholipase A2
Signal tansduction SGK2 NM_016276.3 0.038 down serumglucocorticoid regulated kinase (SGK)
Transcription factors FOXM1 NM_021953.1 0.046 up forkhead box M1 (FOXM1)
Transcription factors GTF2IRD1 NM_016328.1 0.046 up GTF2I repeat domain-containing 1 
(GTF2IRD1)
Transcription factor SOX9 NM_000346.1 0.045 up Sex determining region Y-box 9
ATP-binding/proteins folding HSPH1 BG403660 0.043 up heat shock 105 kD (HSP105B)
Transport solute carrier SLC12A2 NM_001046 0.048 up solute carrier family 12
Cell cycle (proliferation) TPX2 NM_012112.1 0.044 up restricted expressed proliferation associated 
protein
Cell cycle (progression) UBE2C NM_007019.1 0.050 up ubiquitin carrier protein E2-C (UBCH10)
Cell cycle (proliferation) CSE1L/CAS NM_001316 0.052 up CSE1 chromosome segregation 1-like (yeast)
Signal Transduction CCNB1 Hs.23960 0.048 up cyclin B1
Focal adhesion NEBL NM_006393.1 0.038 up nebulette protein 
(NEBL, actin-binding Z-disc protein)
Replication and repair RFC3 BC000149 0.049 up replication factor C (activator 1) 3 (38 kD)BMC Medical Genomics 2009, 2:11 http://www.biomedcentral.com/1755-8794/2/11
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used to obtain expression data under different cellular
conditions: the acute treatment focused on moderate
DNA demethylation to minimize cell viability, and the
chronic treatment to maximize DNA demethylation (see
Additional file 1).
Ten out of the 21 validated genes, i.e. ABCA8, AQP8,
HPGD, PRDX6, SLC26A3, STX12, NDRG2, MXI1, SGK2,
and SCNNB1, were analysed for the impact of their DNA
hypermethylation on epigenetic events (Fig. 2). Other
genes had no epigenetic influence and were, therefore,
excluded from the analysis. Indeed, the underexpression
of NR3C2 and SGK1 has been related to aldosterone reg-
ulation pathway [22], whereas the 14-3-3ε gene modu-
lates the CLCA4 gene by interacting with the calmodulin-
dependent pathway [23]. Demethylation of the 5'-UTRs
Logarithmic expression profile value of twenty-one genes determined by quantitative reverse transcription-PCR by using the  Comparative CT method Figure 1
Logarithmic expression profile value of twenty-one genes determined by quantitative reverse transcription-
PCR by using the Comparative CT method. Three housekeeping genes were used to normalize input cDNA for each 
sample with colorectal cancer, with cDNA of normal tissue used as calibrator. Crosses represents mean of triplicate determi-
nations. *P < 0.05; ° P < 0.01; ^ P < 0.001.
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of some genes with a concomitant increase in mRNA
expression was documented in cell lines (Fig. 2). For
HPGD and NDRG2 genes a 1.4 and 1.3-fold increase in
CaCo2, a 7.0 and 1.6-fold increase in HCT116, and a 4.1
and 1.3-fold increase in SW480, respectively, was
observed. PRDX6 gene expression increased 1.5 and 3.0-
fold in Caco2 and HCT116 cells, respectively. MXI1
showed a 1.8 and 5.0-fold increase in Caco2 and SW480
cells, respectively (Fig. 2).
In silico search verification and Bisulfite Sequencing Analysis (BSA)
Two of the demethylated genes had CpG islands overlap-
ping their putative promoter regions at in silico confirma-
tion. By means of the MethPrimer software, we found 16
CpGs islands located between nucleotides 20,563,460 and
20,564,147 in NDRG2 genes (Fig. 3A and Additional file 2),
and 26 CpGs islands located immediately at the 5' of the
transcription start site and exon 1 (nucleotides 171,170,862
and 171,713,160) in the PRDX6 gene (Fig. 3A).
The methylation status of promoter regions of these puta-
tive tumour-suppressor genes was assessed by BSA in
untreated cell lines, in tumour matched to normal tissues
of one patient, in vitro methylated DNA (IVD) and in nor-
mal lymphocytes (NL). PRDX6 showed dense methyla-
tion only in IVD; NDRG2  showed a significant
methylation in cell lines and in tumour tissue compared
to normal tissue, suggesting a potential epigenetic regula-
tion of the gene (Fig. 3B and Additional file 3). Full meth-
ylation in all 16 CpG sites of the NDRG2 gene was found
in HCT116 and CaCo2 cell lines, and partial methylation
at the 3th CpG site in the SW480 cell line (Fig. 3B).
Histograms depict expression levels of AQP8, HPGD, PRDX6, MXI1, NDRG2, SCNNB1 and SGK2 genes in CaCo2 cell line (A),  HCT116 cell line (B) and SW480 cell line (C) before and after exposure to 5-Aza-CdR determined by quantitative real-time  PCR using the Comparative CT method Figure 2
Histograms depict expression levels of AQP8, HPGD, PRDX6, MXI1, NDRG2, SCNNB1 and SGK2 genes in CaCo2 
cell line (A), HCT116 cell line (B) and SW480 cell line (C) before and after exposure to 5-Aza-CdR determined 
by quantitative real-time PCR using the Comparative CT method. 2^DCt indicates the ratio between the values of CT 
normalized to three housekeeping genes and compared to cDNA of untreated cells used as calibrator. Error bars indicate 
standard deviation from triplicate experiments. p16 gene was used as positive control in the experiments. Statistical signifi-
cance threshold p-value (p < 0.001) for both acute and chronic treatment are shown. Asterisks indicate P < 0.05 values and 
double asterisks indicate P < 0.001 values.
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Quantitation of NDRG2 methylation in paired tumour and 
normal tissue samples of CRC patients
To determine whether hypermethylation of the NDRG2
gene could be ascertained in primary CRC (Table 1), BSA
of 30 primary colon tumour tissues matched to normal
tissues was performed. When compared to their paired
normal tissues, a relative increase of methylation in
tumours was observed in 19 of 30 (63%) CRC patients
(Fig. 4), but the increase was significant in only 3 patients
(χ2 > 5, df = 1, p < 0.05). In four tissue pairs, the relative
methylation was apparently decreased, likely due a low
sensitivity of the detection method. In the remaining
patients figures were unchanged.
Methylation-specific PCR (MSP) assay in colon cancer cell 
lines and primary CRC samples
MSP was performed to examine the methylation status of
CpG islands identified in the NDRG2  gene (see Addi-
tional file 3). The methylation status of the gene was com-
pared with that observed in three usually hypermethilated
genes (p16, APC, and MLH1) in 3 colon cancer cell lines
(HCT116, CaCo2 and SW480) and in 30 paired tumour-
normal tissues. CpG methylation in NDRG2 was detected
in all cell lines and in 8 of the 30 (27%) colorectal cancer
patients (Table 4). No methylation was detected in 30
samples from normal tissue. Hypermethylation of APC,
p16, and MLH1 genes in tumour tissue was found in 3
(10%), 4 (13%) and 6 (20%) patients, respectively, but
not in normal colonic tissue (Table 5).
When relating the NDRG2 methylation status to clinical
pathologic features, no association with age, gender,
tumour site, and MSI status was observed. Conversely, a
significant correlation was found between the NDRG2
methylation and the AJCC stage of the cancer (Z test, p <
0,05) (Table 4).
CpG islands present in putative promoter regions of the two genes of interest Figure 3
CpG islands present in putative promoter regions of the two genes of interest. A. Promoter structure of NDRG2 
gene (the sequence are shown in Additional file 2). The black arrows correspond to NDRG2 primers for BSA assay, the grey 
arrows correspond to NDRG2_M_2 and NDRG2_M primers for MSP assays. B. CpG islands present in NDRG2 (numbered 
from 1 to 16) and PRDX6 (numbered from 1 to 26) genes obtained by MethPrimer software. Methylation status of CpG sites in 
vitro methylated DNA (IVD), normal lymphocytes (NL), three colon cancer cell lines, and in normal (N) and tumor (T) tissue of 
one patient with colorectal cancer. Methylated and unmethylated cytosine residues are indicated with filled and small circles 
while open circles denote partially methylated sites.
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Discussion
Carcinogenesis is a complex event characterized by the
progressive development of genetic and epigenetic aberra-
tions which ultimately result in loss of physiological con-
trol of cell growth and differentiation. The two most
important epigenetic mechanism are represented by the
DNA methylation, the conversion of cytosine into
methyl-cytosine catalyzed by the DNA methyltransferase
And histone modifications [24]. Changes in the DNA
methylation pattern may occur everywhere in the DNA
molecule. Global DNA hypomethylation generally occurs
in centromeric repeats and repetitive sequences and con-
tributes to carcinogenesis by causing chromosomal insta-
bility, reactivation of transposable elements, and loss of
imprinting [25]. Hypermethylation is especially frequent
in CpG islands, i.e. short DNA sequences rich in CpG
dinucleotides, mostly located in the 5'-untranslated
region (5'-UTR) of genes [24]. When CpG islands are
heavily methylated, transcriptional gene silencing gener-
ally occurs. Although the fine mechanisms of regulation
of the "epigenetic" machinery are still poorly understood,
the DNA methylation may switch on or off several genes
and, in particular, those regulating important biological
phenomena, such as cell growth and differentiation [25].
In normal cells, this epigenetic mechanism is involved in
several physiological events, such as the inactivation of X
chromosome in female cells, silencing either paternal or
maternal alleles of "imprinted" genes, and transcriptional
blocking of exogenous integrated genes potentially dan-
gerous for the cell life. However, aberrant DNA methyla-
tion is also relatively common in cancer cells and is likely
to play an important role in cancer initiation and progres-
sion [26].
Since the pioneer studies of Baylin et al. [27], it has been
widely recognized that cancer cells are characterised by
two opposite events: a global hypomethylation which
results in either up-regulation of proto-oncogenes and
induction of genomic instability, favouring both uncon-
trolled cell growth [9] and mutations, and CpG islands
hypermethylation of other genes, the so-called tumour-
suppressor-genes (TSG), which contributes to loss of the
negative control of the cell cycle [12]. Searching for up-
regulated oncogenes and down-regulated TSG is impor-
tant in basic science, especially when an epigenetic mech-
anism (hypomethylation or hypermethylation) is
suspected. In fact, oncogenes and TSG not only may eluci-
date the highly complex molecular derangement in cancer
cells, but also may be used as potential targets for new
therapeutic approaches. DNA methylation is a reversible
phenomenon which can be modulated by specific agents.
An example is represented by demethylating drugs which
can globally reduce the DNA methylation level of TSG
promoters, restoring their normal activity. Interestingly,
some  in vitro experiments have shown that cancer cell
lines reverted to normal phenotype after treatment with
demethylating agent.
The current study was carried out with a three-step design.
First, we specifically looked at up- and down-regulated
genes not yet firmly associated with colon carcinogenesis,
and selected 24 genes for validation with qPCR. A straight
Methylation analysis of the NDRG2 promoter in 30 tumour and normal tissue pairs, evaluated by the bisulfite sequencing anal- ysis Figure 4
Methylation analysis of the NDRG2 promoter in 30 tumour and normal tissue pairs, evaluated by the bisulfite 
sequencing analysis. Data are expressed as the difference in methylation status between tumour and normal tissue.
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correlation between results obtained from qPCR and
those from DNA microarray was found, implying that
DNA microarray technology is a reliable tool to search for
new genes significantly deregulated in cancer [28]. Sec-
ond, we selected 10 of 21 genes (ABCA8, AQP8, HPGD,
PRDX6, SLC26A3, STX12, NDRG2, MXI1, SGK2, and
SCNNB1) as possible targets of epigenetic modifications
in colon cancer, and after treatment with a demethylating
agent, seven of them showed a significant increase of
mRNA expression (AQP8, HPGD, PRDX6, MXI1,
SCNNB1, SGK2 and NDRG2). From an in silico screening,
only 2 genes (PRDX6 and NDRG2) were considered as
possible candidates for the presence of CpG islands in
their 5'-UTR. For the excluded genes, additional mecha-
nisms of transcriptional regulation were hypothesized to
be responsible for their differential expression. Third, to
evaluate the methylation status of PRDX6  an  NDRG2
genes in normal and cancer tissues, as well as in colon
cancer cell lines, bisulphite sequencing analysis was used.
In the PDRX6 gene the methylation status was not differ-
ent from that observed in normal tissue. In the NDRG2
gene a significant methylation status either in colon can-
cer cell lines and in tumour tissue compared to normal tis-
sue was observed. The underexpression of the PRDX6
protein responsible for the red-ox regulation of the cell,
was found to be correlated with loss of function of
NKX3.1 gene, known as TSG [29].
Table 4: Comparison of the clinicopathological features of 30 CRC patients according to the presence of NDRG2 methylation
Number of CRC
with NDRG2 methylation (%)
Number of CRC
without NDRG2 methylation (%)
p value
Age (yrs):
Age <50 4 (13.3) 5 (16.6) ns
Age >50 4 (13.3) 17 (56.6)
Gender
Male 4 (26.7) 11 (73.3) ns
Female 4 (26.7) 11 (73.3)
CRC:
Familiar 2 (25.0) 6 (75.0) ns
Sporadic 6 (27.3) 16 (72.7)
Tumour location:
Proximal colon 2 (22.2) 7 (77.7) ns
Distal colon 6 (28.6) 15 (71.4)
AJCC stage:
00 1  ( 4 . 8 ) n s *
I 1 (12.5) 2 (9.5)
IIa 1 (12.5) 7 (33.3)
IIIb 0 3 (14.3)
IV 6 (75.0) 8 (38.1) < 0,05^
MSI status1
High 1 (25.0) 3 (75.0) ns
Low 1 (33.4) 2 (66.7)
Stable 6 (27.3) 17 (72.7)
Fisher exact test (2-tail); *Pearson Chi-square; ^Z test only for IV AJCC' stage
1Microsatellite instability (MSI) was determined by the mobility shift of PCR products using CC-MSI kit (AB Analitica s.r.l., Padova, Italy, http://
www.abanalitica.com), that include the Bethesda panel microsatellite (BAT25, BAT26, D5S346, D17S250 and D2S123) and other four 
mononucleotide microsatellite loci (NR21, NR24, BAT40 and TGFβRII), in tumours. Tumours showing instability in four or more markers were 
classified as high MSI, those showing it in two marker as low MSI, and those showing no instability as microsatellite-stable.
Table 5: Promoter gene methylation rates in tumour and normal tissue from patients with colorectal cancer (CRC) sorted by tumour 
location
Proximal colon CRC (n = 9) Distal colon CRC (n = 21)
Tumour Normal Tumour Normal
APC 0 0 3 (14%) 0
p16 1 (11%) 0 3 (14%) 0
MLH1 2 (22%) 0 4 (19%) 0BMC Medical Genomics 2009, 2:11 http://www.biomedcentral.com/1755-8794/2/11
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Using these approaches, the NDRG2 gene was selected for
further analysis because: (i) it was suppressed in all colon
cancer cell lines, (ii) its expression may be up-regulated in
all cell lines by 5Aza-CdR treatments, and (iii) it is
involved in important biological process such as cell
growth [30], differentiation [31] and apoptosis [32]. The
NDRG2 gene is a new member of the N-myc downstream-
regulated gene (NDRG) family, that is located on chromo-
some 14q11.2 and encodes for a 41 kDa protein. It has
been proposed that the NDRG2 gene is a candidate TSG,
and its expression is low or undetectable in several pri-
mary tumour and tumour cell lines [30,33,34]. Liu et al.
[35] revealed that the down-regulation reported in cancer
be driven by promoter methylation, mutation, and
genomic deletion of the NDRG2  gene. Recently, it has
been shown that expression of the NDRG2 protein is
modulated by the insulin-stimulated Akt-dependent
phosphorylation [36]. Several studies have suggested that
the NDRG2 mRNA is down-regulated or undetectable in
a number of human primary cancers, such as squamous
cell carcinoma, pancreatic cancer [37], glioblastoma [30],
and cancer cell-lines. Recently, Zhang et al. [38] have dem-
onstrated that c-Myc represses NDRG2 gene expression via
Miz-1-dependent interaction with NDRG2 core promoter
region, and this inverse regulatory relationship induces
cell differentiation and proliferation.
The MSP assay was used to check for NDRG2 methylation
status in 30 primary colon tumour tissues compared to
normal colonic mucosal samples. After sorting colon can-
cer patients by age, gender, tumour site, and MSI status,
no statistically significant association was observed
between these features and the NDRG2 methylation. Nev-
ertheless, there was a trend towards NDRG2 methylation
status with an advanced tumour stage of the CRC samples,
with significant value detected in patients with AJCC stage
IV (p < 0.05). These results are in agreement with those
reported in other cancer types [34,39] where NDRG2
expression is reduced in high-grade compared to low-
grade tumours. In particular, Lorentzen et al. [39] sug-
gested that in CRC samples the down-regulation of
NDRG2 expression occurs during the progression from
adenoma to carcinoma.
Conclusion
In conclusion, we showed that NDRG2 expression is fre-
quently suppressed in colon cancer cell lines in conjunc-
tion with aberrant DNA methylation, and that the loss of
expression of this gene could be related to advanced colon
tumour stage.
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